Drug
Orforglipron
Orforglipron: highest development phase Phase 3, developed by Eli Lilly. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Orforglipron NCT07794579 | Phase 3 | Overweight |
| Orforglipron NCT07668336 | Phase 3 | Diabetes Mellitus, Type 2 |
| Orforglipron NCT06186622 | Phase 1 | Healthy |
Latest
No recent events.
Follow Orforglipron on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.